I’m joined by Dr. Annika Bergbauer, economist, IT management consultant, and host of Datenaffaire, to explore how we can put people at the centre of data-driven decisions. We discuss stakeholder engagement, clear communication, and the human skills that help us turn technical work into practical impact.
I’m joined by Dr. Annika Bergbauer, economist, IT management consultant, and host of Datenaffaire, to explore how we can put people at the centre of data-driven decisions. We discuss stakeholder engagement, clear communication, and the human skills that help us turn technical work into practical impact.
I’m joined by Dr. Annika Bergbauer, economist, IT management consultant, and host of Datenaffaire, to explore how we can put people at the centre of data-driven decisions. We discuss stakeholder engagement, clear communication, and the human skills that help us turn technical work into practical impact.
How can statisticians improve dose decisions and drive innovation in their everyday work?
I speak with Marie-Karelle Rivière and Anaïs Andrillon from Saryga about Project Optimus, their approach to dose optimization, and what it takes to turn challenging questions into meaningful research.
How can statisticians improve dose decisions and drive innovation in their everyday work?
I speak with Marie-Karelle Rivière and Anaïs Andrillon from Saryga about Project Optimus, their approach to dose optimization, and what it takes to turn challenging questions into meaningful research.
How can statisticians improve dose decisions and drive innovation in their everyday work?
I speak with Marie-Karelle Rivière and Anaïs Andrillon from Saryga about Project Optimus, their approach to dose optimization, and what it takes to turn challenging questions into meaningful research.
How can we make statistics meaningful to someone who does not work with it every day?
I talk with Steve Mallett about his work with the PSI Schools team and the lessons it offers for training colleagues in pharma. We explore how hands-on activities, interactive data visualization, and a clear understanding of the audience can help people connect statistical concepts to patients and speak about results with greater confidence.
How can we make statistics meaningful to someone who does not work with it every day?
I talk with Steve Mallett about his work with the PSI Schools team and the lessons it offers for training colleagues in pharma. We explore how hands-on activities, interactive data visualization, and a clear understanding of the audience can help people connect statistical concepts to patients and speak about results with greater confidence.
How can we make statistics meaningful to someone who does not work with it every day?
I talk with Steve Mallett about his work with the PSI Schools team and the lessons it offers for training colleagues in pharma. We explore how hands-on activities, interactive data visualization, and a clear understanding of the audience can help people connect statistical concepts to patients and speak about results with greater confidence.
What does “quality” really mean in statistical programming?
In this episode of The Effective Statistician, I speak with Andrew (Andy) York about the evolving world of programming validation, traceability, and quality assurance in clinical trials. Andy has decades of experience in statistical programming, leadership roles across pharma and CROs, and now works with AI-driven solutions focused on improving validation and traceability.
We discuss why traditional approaches to validation are becoming increasingly difficult to sustain, how expectations from regulators continue to grow, and why traceability is far more than just linking programs and datasets.
Andy also shares how modern AI-powered tools can automatically map programming workflows, connect datasets and outputs, and create end-to-end traceability from raw data to final tables, figures, and listings.
If you work with statistical programming, clinical data workflows, submissions, or validation processes, this episode will challenge some long-held assumptions and introduce you to where the future may be heading.
What does “quality” really mean in statistical programming?
In this episode of The Effective Statistician, I speak with Andrew (Andy) York about the evolving world of programming validation, traceability, and quality assurance in clinical trials. Andy has decades of experience in statistical programming, leadership roles across pharma and CROs, and now works with AI-driven solutions focused on improving validation and traceability.
We discuss why traditional approaches to validation are becoming increasingly difficult to sustain, how expectations from regulators continue to grow, and why traceability is far more than just linking programs and datasets.
Andy also shares how modern AI-powered tools can automatically map programming workflows, connect datasets and outputs, and create end-to-end traceability from raw data to final tables, figures, and listings.
If you work with statistical programming, clinical data workflows, submissions, or validation processes, this episode will challenge some long-held assumptions and introduce you to where the future may be heading.
What does “quality” really mean in statistical programming?
In this episode of The Effective Statistician, I speak with Andrew (Andy) York about the evolving world of programming validation, traceability, and quality assurance in clinical trials. Andy has decades of experience in statistical programming, leadership roles across pharma and CROs, and now works with AI-driven solutions focused on improving validation and traceability.
We discuss why traditional approaches to validation are becoming increasingly difficult to sustain, how expectations from regulators continue to grow, and why traceability is far more than just linking programs and datasets.
Andy also shares how modern AI-powered tools can automatically map programming workflows, connect datasets and outputs, and create end-to-end traceability from raw data to final tables, figures, and listings.
If you work with statistical programming, clinical data workflows, submissions, or validation processes, this episode will challenge some long-held assumptions and introduce you to where the future may be heading.
In this episode, I speak with Anna Mosikian, a physician by training and Global Clinical Program Lead working at the intersection of clinical development and strategic marketing.
Anna brings a powerful perspective on how clinical data translates into real-world value—bridging evidence generation, regulatory expectations, and commercial impact. We dive into what clinical leaders truly expect from statisticians and how statisticians can move from technical contributors to strategic partners.
We explore what “good collaboration” really looks like in practice, why understanding the purpose of a study is critical, and how statisticians can elevate their impact through communication, proactiveness, and cross-functional thinking.
In this episode, I speak with Anna Mosikian, a physician by training and Global Clinical Program Lead working at the intersection of clinical development and strategic marketing.
Anna brings a powerful perspective on how clinical data translates into real-world value—bridging evidence generation, regulatory expectations, and commercial impact. We dive into what clinical leaders truly expect from statisticians and how statisticians can move from technical contributors to strategic partners.
We explore what “good collaboration” really looks like in practice, why understanding the purpose of a study is critical, and how statisticians can elevate their impact through communication, proactiveness, and cross-functional thinking.
In this episode, I speak with Anna Mosikian, a physician by training and Global Clinical Program Lead working at the intersection of clinical development and strategic marketing.
Anna brings a powerful perspective on how clinical data translates into real-world value—bridging evidence generation, regulatory expectations, and commercial impact. We dive into what clinical leaders truly expect from statisticians and how statisticians can move from technical contributors to strategic partners.
We explore what “good collaboration” really looks like in practice, why understanding the purpose of a study is critical, and how statisticians can elevate their impact through communication, proactiveness, and cross-functional thinking.
In this episode, I sit down with Rachael Lawrance to dive into a topic that has become absolutely central to clinical research: patient-centered outcomes.
When I first started as a statistician, I knew these measures existed—but I didn’t really understand how they were developed, analyzed, or used in decision-making. That has changed dramatically over the years. Today, patient-reported outcomes (PROs) and the broader framework of clinical outcome assessments (COAs) play a key role in regulatory approvals, payer decisions, and how we demonstrate treatment value.
Rachael brings deep expertise from her work at Adelphi Values and shares how these endpoints are developed, validated, and applied in practice. We also discuss how statisticians can contribute more effectively by understanding the science behind these measures—not just treating them as “just another scale.”
In this episode, I sit down with Rachael Lawrance to dive into a topic that has become absolutely central to clinical research: patient-centered outcomes.
When I first started as a statistician, I knew these measures existed—but I didn’t really understand how they were developed, analyzed, or used in decision-making. That has changed dramatically over the years. Today, patient-reported outcomes (PROs) and the broader framework of clinical outcome assessments (COAs) play a key role in regulatory approvals, payer decisions, and how we demonstrate treatment value.
Rachael brings deep expertise from her work at Adelphi Values and shares how these endpoints are developed, validated, and applied in practice. We also discuss how statisticians can contribute more effectively by understanding the science behind these measures—not just treating them as “just another scale.”
In this episode, I sit down with Rachael Lawrance to dive into a topic that has become absolutely central to clinical research: patient-centered outcomes.
When I first started as a statistician, I knew these measures existed—but I didn’t really understand how they were developed, analyzed, or used in decision-making. That has changed dramatically over the years. Today, patient-reported outcomes (PROs) and the broader framework of clinical outcome assessments (COAs) play a key role in regulatory approvals, payer decisions, and how we demonstrate treatment value.
Rachael brings deep expertise from her work at Adelphi Values and shares how these endpoints are developed, validated, and applied in practice. We also discuss how statisticians can contribute more effectively by understanding the science behind these measures—not just treating them as “just another scale.”